AONN+ Conference Abstracts

Acalabrutinib is a highly selective, potent, covalent Bruton tyrosine kinase inhibitor, approved for use in adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL), an aggressive B-cell malignancy.

Hairy cell leukemia (HCL) is a rare B-cell malignancy, diagnosed in ~1000 new patients a year in the US.

Ibrutinib, a first-in-class, once-daily inhibitor of Bruton tyrosine kinase (BTK), is approved in the US for the treatment of CLL/SLL and allows for treatment without chemotherapy.

Ibrutinib, a first-in-class, once-daily inhibitor of Bruton tyrosine kinase, is approved in the US for CLL/SLL treatment, including in combination with obinutuzumab.

Twelve months of adjuvant oral dabrafenib + trametinib therapy significantly prolonged relapse-free survival versus placebo in patients with resected BRAF V600E/K–mutant stage III melanoma.

Individuals with hereditary breast and ovarian cancer syndrome (HBOC), caused by mutations in BRCA1 and BRCA2, have some of the highest cancer incidences of any known group.

Travel and global military presence dictate that international diseases can affect the American populace.

While adherence to annual screening exceeded 90% in the National Lung Screening Trial, the trial population was disproportionately white, educated, and received care in the tightly controlled environment of a clinical trial.

Lung cancer is the leading cause of cancerrelated death for men and women in the United States.

Hispanics have unique healthcare needs and face significant health disparities.